Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Chen Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0578-7589; OpenAlex author ID A5059738737. Sources: OpenAlex.

Their work

Papers
75 (first author 4, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
97
Papers, trials and grants by year

2015: 2 papers · 2016: 7 papers · 2017: 7 papers · 2018: 8 papers · 2019: 10 papers · 2020: 11 papers · 2021: 11 papers · 2022: 3 papers · 2023: 7 papers · 2024: 4 papers · 2025: 4 papers · 2026: 1 paper

Papers 50 of 75

  1. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Last author DOI 10.1016/j.tranon.2025.102624↗
  2. Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Co-author DOI 10.1038/s41419-025-07495-2↗
  3. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  4. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Last author DOI 10.1097/js9.0000000000002242↗
  5. Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030. Co-author DOI 10.3389/fonc.2025.1660313↗
  6. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.csbj.2024.04.021↗
  7. Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ebiom.2024.105098↗
  8. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Last author DOI 10.1016/j.surg.2023.12.019↗
  9. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
  10. Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxi… Co-author DOI 10.1016/j.tranon.2023.101692↗
  11. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  12. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2022-329349↗
  13. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarc… Co-author DOI 10.1186/s13063-023-07456-0↗
  14. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Prelimin… Co-author DOI 10.3390/curroncol30030228↗
  15. Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Can… Co-author DOI 10.3390/ijms24043270↗
  16. Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer. Co-author DOI 10.3390/ijms24043476↗
  17. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2021.121306↗
  18. Long noncoding RNA HOXD-AS1 promotes the progression of pancreatic cancer through miR-664b-3p/PLAC8 axis. Co-author DOI 10.1016/j.prp.2022.153836↗
  19. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Last author DOI 10.1038/s41388-022-02306-w↗
  20. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00018-021-03866-y↗
  21. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  22. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. Last author DOI 10.1186/s12943-021-01400-z↗
  23. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic rev… Co-author DOI 10.21037/gs-21-16↗
  24. Role of LRG1 in the Cell Proliferation, Migration, and Prognosis of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-733520/v1↗
  25. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.648917↗
  26. Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. Co-author DOI 10.3389/fonc.2021.640820↗
  27. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.643465↗
  28. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. Last author DOI 10.3389/fonc.2021.674897↗
  29. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Last author DOI 10.3390/ijms222010944↗
  30. Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. Co-author DOI 10.7150/ijbs.59117↗
  31. Hypoxia: a barricade to conquer the pancreatic cancer. Last author DOI 10.1007/s00018-019-03444-3↗
  32. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2020.119907↗
  33. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Co-author DOI 10.1080/15548627.2019.1628540↗
  34. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. First author DOI 10.1097/sla.0000000000002998↗
  35. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317163↗
  36. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Last author DOI 10.18632/aging.104134↗
  37. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.18632/aging.202199↗
  38. The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. Co-author DOI 10.21037/atm-20-2554a↗
  39. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. First author DOI 10.7150/thno.40566↗
  40. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. Co-author DOI 10.7717/peerj.9602↗
  41. Tetraspanin CD9 interacts with α-secretase to enhance its oncogenic function in pancreatic cancer. Co-author PMID 33042435↗
  42. The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. First author DOI 10.1002/jso.25690↗
  43. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. First author DOI 10.1002/smll.201900631↗
  44. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. Co-author DOI 10.1021/acs.nanolett.9b00374↗
  45. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002668↗
  46. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-18-1968↗
  47. The microbiota and microbiome in pancreatic cancer: more influential than expected. Co-author DOI 10.1186/s12943-019-1008-0↗
  48. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Co-author DOI 10.1186/s12943-019-1117-9↗
  49. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40425-019-0703-0↗
  50. Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. Co-author DOI 10.3390/cancers11121998↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 67 shared papers, 2015–2026 · strength 7.76
  2. Si Shi · 62 shared papers, 2016–2024 · strength 6.69
  3. Qingcai Meng · 51 shared papers, 2017–2026 · strength 6.57
  4. Jin Xu · 57 shared papers, 2016–2025 · strength 6.24
  5. Jie Hua · 43 shared papers, 2018–2026 · strength 5.73
  6. Wei Wang · 17 shared papers, 2021–2026 · strength 2.65
  7. Zhen Tan · 13 shared papers, 2019–2026 · strength 2.09
  8. Bo Zhang · 15 shared papers, 2017–2024 · strength 1.99
  9. Rong Tang · 12 shared papers, 2020–2025 · strength 1.81
  10. Quanxing Ni · 22 shared papers, 2016–2020 · strength 1.56
  11. Dingkong Liang · 19 shared papers, 2016–2019 · strength 1.26
  12. Zeyin Rong · 6 shared papers, 2021–2026 · strength 1.20
  13. Miaoyan Wei · 8 shared papers, 2019–2026 · strength 1.17
  14. Yi Qin · 18 shared papers, 2016–2020 · strength 1.13
  15. Yiyin Zhang · 10 shared papers, 2018–2023 · strength 1.10
  16. Shunrong Ji · 17 shared papers, 2016–2020 · strength 1.07
  17. Xiaomeng Liu · 7 shared papers, 2019–2025 · strength 0.99
  18. Jianhui Yang · 4 shared papers, 2021–2026 · strength 0.84
  19. Jiang Liu · 8 shared papers, 2016–2021 · strength 0.83
  20. Wenyan Xu · 13 shared papers, 2016–2018 · strength 0.73
  21. Qiong Du · 3 shared papers, 2023–2025 · strength 0.57
  22. Abudureyimu Tuerhong · 3 shared papers, 2021–2024 · strength 0.50
  23. Jinfeng Xiang · 8 shared papers, 2016–2018 · strength 0.47
  24. Heng Zhu · 2 shared papers, 2024–2025 · strength 0.43
  25. Bo Zhang · 2 shared papers, 2024–2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.